Suzhou Abogen Biosciences Co., Ltd.

This study tests a new mRNA vaccine (ABO1105) for respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive one injection of either a low or high dose of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune res…

This study tests a new mRNA vaccine (ABO1108) to see if it can safely prevent shingles in adults aged 40 and older. About 300 healthy volunteers or those with stable health conditions will receive two shots, two months apart. Researchers will measure the body's immune response an…

This early-stage trial tests a new mRNA vaccine (ABO1108) to prevent shingles in 180 healthy adults aged 40 and older. Participants receive two shots about two months apart at different dose levels. The main goal is to check the vaccine's safety and how well the body responds to …

This early-stage trial tests a new mRNA vaccine (ABO1105) for respiratory syncytial virus (RSV) in 96 healthy adults aged 18 and older. The main goal is to check the vaccine's safety and how well the body's immune system responds. Participants receive one injection at different d…